surpass 3 tirzepatide Once-weekly versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase trial Overview of the SURPASS phase

In recent years, autophagy, as a critical lysosome-dependent self-degradative process to maintain homeostasis, has been shown to be involved in the vascular endothelium damage in diabetes

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants 45 years of age with a body mass index 27 kg/m2 with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or placebo

Consistently using the same spot can lead to skin irritation, scarring, or hard lumps under the skin

Our finding of similar incidence of non-fatal cardiovascular outcomes with GLP1-RA compared to DPP4i is in line with the recently published FLOW study that randomized people with early to mid-stage CKD to semaglutide or placebo, which reported similar incidence of non-fatal myocardial infarction and non-fatal stroke across the semaglutide and placebo treated groups, despite a significantly reduced risk of major kidney disease events and all-cause death 44